Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours

Area of Science:

• Oncology
• Clinical Pharmacology
• Biostatistics

Background:

• Chemotherapy-induced neutropenia is a significant toxicity, increasing morbidity, mortality, and healthcare costs.
• Prophylactic granulocyte colony-stimulating factors are recommended for high-risk patients to mitigate neutropenia.
• Predicting neutropenia is crucial for personalized chemotherapy management and dose adjustments.

Purpose of the Study:

• To develop and validate a predictive model for first-cycle chemotherapy-induced neutropenia in patients with solid tumors.
• To identify key clinical factors influencing the occurrence of severe neutropenia.
• To aid in clinical decision-making for chemotherapy administration and supportive care.

Main Methods:

• A multi-center, non-interventional prospective cohort study included 1194 patients with solid tumors.
• A predictive logistic regression model was developed using patient data.
• Factors analyzed included Eastern Cooperative Oncology Group (ECOG) status, baseline lymphocyte and neutrophil counts, sex, and treatment intention.

Main Results:

• Higher ECOG status (ECOG 2 vs. 0) significantly increased neutropenia risk (OR 3.12, P=0.003).
• Baseline lymphocyte (OR 0.67, P=0.011) and neutrophil counts (OR 0.90, P=0.026) were inversely associated with neutropenia.
• The model demonstrated a negative predictive value of 94%, suggesting its utility in ruling out neutropenia.

Conclusions:

• A predictive model incorporating ECOG status and baseline blood counts can identify patients at risk of chemotherapy-induced neutropenia.
• The model shows potential as a valuable tool for clinical decision-making in oncology.
• Further validation is recommended to confirm its clinical utility in managing chemotherapy toxicity.